Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2025 08:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the...
May 16, 2025 16:48 ET | Source: NMDP

NMDP℠ Partners with Lil Miquela to Encourage Young People to Join the Blood Stem Cell Donor Registry and Help Save Patient Lives

NMDP partners with Lil Miquela, a 22-year-old virtual influencer with millions of fans, to grow NMDP Registry and help save patient lives.
March 20, 2025 16:05 ET | Source: Vor Biopharma

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment...
December 10, 2024 07:00 ET | Source: IN8bio, Inc

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
December 06, 2024 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
December 03, 2024 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
November 26, 2024 05:00 ET | Source: ImCheck Therapeutics SAS

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...
November 22, 2024 15:37 ET | Source: Gift of Life Marrow Registry

9-Year Old Rare Blood Disorder Survivor Meets Lifesaving Donor at Gift of Life Marrow Registry Gala

Miami Beach Event Honored Emilio Estefan, Jr., Vice Mayor Alex Fernandez and Boucher Brothers for their Distinguished Advocacy BOCA RATON, Fla., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Gift of Life...
November 21, 2024 05:07 ET | Source: Pentixapharm Holding AG

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that...
October 25, 2024 04:07 ET | Source: Research and Markets

Understanding the United States Chronic Lymphocytic Leukemia (CLL) Patient Journey to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges

Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: Understanding the CLL Patient Experience" report has been added to ResearchAndMarkets.com's...

Next Page keyboard_arrow_right